OptiScan, maker of glucose monitoring devices, raises $2.6M

OptiScan Biomedical pulled in $2.6 million in new funding, according to a regulatory filing. The Hayward, CA, company makes non-invasive bedside glucose monitoring devices for the hospital intensive care unit. OptiScan's SEC filing does not disclose specific investors involved or for what purpose the money will be used. But OptiScan's website notes that the company will expand the ability of its glucose monitoring devices to detect "additional analytes within the same blood sample." SEC Filing

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.